Geovax Labs Inc Share Price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
14/05 | Transcript : GeoVax Labs, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
28/03 | GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.4M 366M |
---|---|---|---|---|---|
Net income 2024 * | -31M -2.58B | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.01
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.55% |
Latest transcript on Geovax Labs Inc
Managers | Title | Age | Since |
---|---|---|---|
David Dodd
CEO | Chief Executive Officer | 74 | 17/10/17 |
Mark Reynolds
DFI | Director of Finance/CFO | 62 | 01/06/01 |
Erica Raiden
CTO | Chief Tech/Sci/R&D Officer | - | 07/22/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert McNally
BRD | Director/Board Member | 76 | 01/06/01 |
Randal Chase
BRD | Director/Board Member | 74 | 19/15/19 |
John Spencer
BRD | Director/Board Member | 83 | 28/06/28 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |